文献速递类风湿关节炎

Vamorolone:一种新型抗代谢性类固醇,可抑制慢性多关节炎关节破坏并减少全身副作用

Vamorolone: a novel metabolism resistant steroid that suppresses joint destruction in chronic polyarthritis with reduced systemic side effects.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该研究在体外证实Vamorolone完全抵抗11β-HSD1代谢,并在TNFtg小鼠多关节炎模型中比较Vamorolone 20 mg/kg/天、泼尼松龙与溶媒灌胃至56日龄的效果;Vamorolone抗炎作用与泼尼松龙相当,但未出现肾上腺萎缩、体重下降、肌肉消耗或骨合成代谢抑制等典型糖皮质激素副作用。

要点

  • Vamorolone在体外完全抵抗11β-HSD1代谢。
  • TNFtg小鼠中Vamorolone 20 mg/kg/天抗炎作用与泼尼松龙相当。
  • Vamorolone未出现肾上腺萎缩、体重下降、肌肉消耗或骨合成代谢抑制。

核心结论

  • 在本研究考察的有效抗炎剂量下,Vamorolone相较泼尼松龙具有更少的全身不良效应谱。
  • Vamorolone在炎症性疾病中更广泛应用的可能性被提出,但在显著更高剂量下这些副作用是否仍保持轻微尚不清楚。

研究设计与样本

  • 体外研究:在Hs68细胞和原代白细胞培养中检测11β-HSD1代谢与作用。
  • 动物研究:TNFtg或TNFtg 11β-HSD1敲除(TNFtg11BKOKO)小鼠经灌胃给予Vamorolone 20 mg/kg/天、泼尼松龙(标准治疗)或溶媒,每日评分体重与疾病严重度,于56日龄评估炎症、关节破坏及副作用标志物。

主要发现

  • Vamorolone在体外完全抵抗11β-HSD1代谢。
  • TNFtg小鼠中Vamorolone相较泼尼松龙在关节炎症、血清白细胞介素-6(IL-6)和滑膜炎方面呈可比性降低。
  • Vamorolone治疗小鼠未出现典型糖皮质激素副作用,包括肾上腺萎缩、体重下降、肌肉消耗或骨合成代谢抑制。
  • 上述获益在11β-HSD1敲除小鼠中持续存在,提示Vamorolone疗效在很大程度上不依赖11β-HSD1代谢。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出在显著更高剂量下这些副作用是否仍保持轻微尚不清楚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Vamorolone, a dissociated steroidal compound with reduced side effects, offers a promising alternative to traditional glucocorticoids for inflammatory diseases. Unlike conventional glucocorticoids, vamorolone lacks the hydroxyl or ketone groups required for metabolism by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), a key enzyme that modulates glucocorticoid activity. This study investigates vamorolone's resistance to 11β-HSD1 metabolism and assesses its therapeutic efficacy in the murine tumour necros factor-alpha-overexpressing (TNFtg) model of polyarthritis. METHODS: 11β-HSD1 metabolism and action were examined in Hs68 and primary leucocyte culture. Vamorolone 20 mg/kg/day, prednisolone (standard of care) or vehicle were administered by gavage to TNFtg or TNFtg 11β-HSD1 knock-out (TNFtg11BKOKO) animals. Body weight and disease severity were scored daily, and markers of inflammation, joint destruction and side effects assessed at day 56 of age. RESULTS: Vamorolone was entirely resistant to 11β-HSD1 metabolism in vitro. Vamorolone demonstrated comparable anti-inflammatory actions in TNFtg mice, with a comparable reduction in joint inflammation, serum interleukin-6 (IL-6) and synovitis relative to prednisolone. However, vamorolone-treated mice did not experience typical glucocorticoid side effects, including adrenal atrophy, body weight reduction, muscle wasting or inhibition of anabolic bone metabolism. These benefits persisted in 11β-HSD1 knockout mice, indicating that the efficacy of vamorolone is largely independent of 11β-HSD1 metabolism. CONCLUSION: The findings suggest that at the effective anti-inflammatory dose examined in this study, vamorolone possesses a reduced profile of deleterious systemic effects relative to prednisolone. Whilst highlighting its potential for broader clinical application in inflammatory conditions, it remains unclear whether these side effects would remain mild at markedly higher doses.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Crastin A, Shanker A, Sagmeister MS, et al. Vamorolone: a novel metabolism resistant steroid that suppresses joint destruction in chronic polyarthritis with reduced systemic side effects. Rheumatology (Oxford). 2025. PMID: 40169170. doi:10.1093/rheumatology/keaf129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。